*.- PharmaMar Announces Top line Results for PM01183 Phase II trial in Patients with Platinum Resistant/Refractory Ovarian Cancer .
*.- 30.3% of patients with platinum resistant disease responded to treatment with PM01183, while no patients in the topotecan arm responded .
*.- 82% of patients with platinum resistant disease treated with PM01183 compared to 50% of patients treated with topotecan exhibited a clinical benefit .
*.- The median progression-free survival (PFS) in resistant disease was 4.8 months for PM01183 and 1.7 months for topotecan (p=0.0004) .
*.- Although survival data is not yet mature, a significant increase in overall survival was observed in patients treated with PM01183 compared to topotecan .
...